Company Overview and News
Shares of Intel Corp. INTC, +0.54% are down 1.1% in premarket trading Tuesday after Raymond James analyst Chris Caso downgraded the stock to underperform from market perform due to "a number of headwinds mounting against the company, set to impact longer-term growth expectations and profitability." He said that his meetings show more optimism for Intel competitors than in past years. "Intel's well documented CPU shortage persists through the September quarter," Caso wrote.
ADI AMD INTC MCHP ON
While they are a usually controversial subject, stock buybacks have nonetheless made a huge impact this year. According to a CNBC report last month, companies will likely purchase $1 trillion worth of their own equity. Understandably, this trend has Wall Street considering the pros and cons.
JWN STLD AMZN TMO ADI M MSFT ROK NUE ORCL
U.S.-based telecom sector stocks have been soaring amid progress towards advancing 5G (next generation) technology and despite global competition.
XLNX K3ED CHLKF CHJHF TMUS CMCSA CHA 0941 0762 CHL CHUFF ADI VZ 0728 CCI CHU QCOM
Wireless use in the United States and around the world is now pretty much ubiquitous, and it looks to stay that way for the foreseeable future. Plus, when you consider the devices that use wireless, the increase in capability and function since the release of the first smartphones just over 10 years has been tremendous and shall continue to stay that way one can only assume.
SWKS SMTC ADI
Microsemi channel inventory issues, lead times, and trade-related business confidence are near-term challenges for the outlook, but Microchip is well-placed in attractive MCU and analog markets.
2018-09-12 marketwatch - 1
Chip stocks were hammered for a second day Wednesday as more analysts accepted that memory chip demand for the remainder of the year will not be as strong as expected as recently as a few months ago.
LRCX SWKS TER TXN ENTG AMAT AAPL ADI AMD NVDA MXIM
2018-09-04 seekingalpha - 1
The top three positions are Henry Schein, Dentsply Sirona, and Cooper Companies and they add up to ~23% of the entire portfolio.
JD BAP TXN TMO ADP GOOG CRM AYI.WI COO NKE AMZN IR CERN MELI AYI WSBF WSCC MA INFY MCHP HSIC CMG MULE V XRAY ADPVV GOOGL ADI INFY JLL WAT MSFT APTV
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ADI / Analog Devices, Inc. on message board site Silicon Investor.
as of ET